ArticlePloS one2025
EBV-miR-BART5-5p regulates RORA to promote proliferation and migration of gastric cancer cells.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Epstein-Barr virus-driven immunosuppression in nasopharyngeal carcinoma: a comprehensive review of viral mechanisms, spatial tumor ecosystems, and precision therapeutics.Frontiers in immunology · 2026Pooled it
- Integrating single-cell multi-omics and machine learning to reveal triaptosis heterogeneity in clear cell renal cell carcinoma.Human genomics · 2026Article
- The research progress of the synergistic effect of Epstein-Barr virus andFrontiers in oncology · 2026Review
- Circadian clock and cancer.Military Medical Research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEpstein-Barr virus-associated gastric cancer (EBVaGC) represents a distinct molecular subtype of gastric cancer. EBV encodes various viral RNAs, including BamHI-A rightward transcripts (BARTs), which are implicated in the carcinogenic processes of EBVaGC. This study aims to explore the function and underlying mechanisms of EBV-miR-BART5-5p in gastric cancer, providing a basis for the identification of more effective biomarkers for EBVaGC.
methodsGene expression data were first downloaded from the GSE51575 dataset to identify differentially expressed genes and construct a WGCNA network, which led to the identification of RORA as a key gene associated with EBV-miR-BART5-5p. We then analyzed the TCGA dataset to investigate the differential expression and prognostic significance of RORA in gastric cancer. Further analysis explored RORA's enriched pathways and its relationship with immune response, tumor mutation burden, and drug sensitivity. Single-cell gene expression characteristics of RORA were assessed using the GSE134520 dataset. RT-qPCR was employed to determine RORA expression levels in both EBV-positive and -negative gastric cancer cell lines. Western blotting and dual-luciferase reporter assays confirmed the targeting of RORA's 3' UTR by EBV-miR-BART5-5p. Finally, a series of functional experiments demonstrated that EBV-miR-BART5-5p promotes proliferation and migration of both EBV-positive and -negative gastric cancer cells.
resultsIn this study, differential expression and WGCNA analyses identified 910 co-expressed genes. We then investigated miR-BART5-5p in EBV-positive gastric cancer and identified RORA as a potential target gene. Our analysis revealed that RORA expression is lower in tumor samples compared to normal samples, and single-cell analysis showed significant upregulation of RORA in CD8 + T cells. Experimental data further demonstrated that RORA is expressed at lower levels in EBV-positive gastric cancer cell lines and that EBV-miR-BART5-5p targets the 3' UTR of RORA. This suggests that EBV-miR-BART5-5p may promote gastric cancer cell proliferation and migration by regulating RORA.
conclusionOur study reveals the molecular characteristics of EBV-associated gastric cancer, establishes a prognostic model for RORA in gastric cancer, and demonstrates that EBV-miR-BART5-5p may target and inhibit RORA to promote gastric cancer cell proliferation and migration. These findings highlight EBV-miR-BART5-5p could serve as a diagnostic biomarker and a potential therapeutic target for gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.